These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25512636)

  • 1. Melanoma BRAF fusions--response.
    Hutchinson KE; Ross JS; Stephens PJ; Miller VA; Sosman JA; Pao W
    Clin Cancer Res; 2014 Dec; 20(24):6632. PubMed ID: 25512636
    [No Abstract]   [Full Text] [Related]  

  • 2. Melanoma BRAF fusions--letter.
    Botton T; Yeh I; Bastian BC
    Clin Cancer Res; 2014 Dec; 20(24):6631. PubMed ID: 25512635
    [No Abstract]   [Full Text] [Related]  

  • 3. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
    Nathan P; Sharma A; Lorigan P
    Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 5. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
    Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
    Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF inhibitors: research accelerates in wake of positive findings.
    Brower V
    J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
    [No Abstract]   [Full Text] [Related]  

  • 7. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
    Ezra N; Hamid O; Behroozan D
    Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
    [No Abstract]   [Full Text] [Related]  

  • 8. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
    Schadendorf D
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
    [No Abstract]   [Full Text] [Related]  

  • 9. BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.
    Richtig E; Schrama D; Ugurel S; Fried I; Niederkorn A; Massone C; Becker JC
    Br J Dermatol; 2013 Feb; 168(2):428-30. PubMed ID: 22775439
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
    Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
    J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
    [No Abstract]   [Full Text] [Related]  

  • 11. [Gene abnormalities in melanoma and signal transduction antagonists].
    Takada M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
    [No Abstract]   [Full Text] [Related]  

  • 12. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H; Gutschi M; Welzel J; Haas C
    J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
    [No Abstract]   [Full Text] [Related]  

  • 14. What, if Any, Role Is There for BRAF-Targeted Therapy in
    Sullivan RJ
    J Clin Oncol; 2022 Dec; 40(36):4161-4165. PubMed ID: 35862870
    [No Abstract]   [Full Text] [Related]  

  • 15. Selumetinib increases the efficacy of first-line dacarbazine.
    Cancer Discov; 2013 Jul; 3(7):OF16. PubMed ID: 23847359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of triple therapy in BRAF-positive melanoma.
    Sullivan RJ
    Clin Adv Hematol Oncol; 2022 Jun; 20(6):359-361. PubMed ID: 35731606
    [No Abstract]   [Full Text] [Related]  

  • 17. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting metastatic melanoma.
    Flaherty KT
    Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.
    Mesbah Ardakani N; Leslie C; Grieu-Iacopetta F; Lam WS; Budgeon C; Millward M; Amanuel B
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):233-242. PubMed ID: 28002643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
    Bahadoran P; Allegra M; Le Duff F; Long-Mira E; Hofman P; Giacchero D; Passeron T; Lacour JP; Ballotti R
    J Clin Oncol; 2013 Jul; 31(19):e324-6. PubMed ID: 23715574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.